FindTrial
Sign In

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01984697
Enrollment
1518
Registered
2013-11-15
Start date
2013-12-12
Completion date
2017-07-24
Last updated
2018-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Papillomavirus Infection

Brief summary

This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age. From this study, the goal was to establish that the investigational 2-dose regimens (0, 6 months and 0, 12 months) studied in boys and girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response that is not inferior to that observed in young women 16 to 26 years of age who received the standard 3-dose regimen of V503 (i.e., the population and dose regimen used to establish V503 efficacy).

Interventions

BIOLOGICALV503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)

V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

Sponsors

Merck Sharp & Dohme LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
9 Years to 26 Years
Healthy volunteers
Yes

Inclusion criteria

All Participants: -Judged to be in good physical health on the basis of medical history, physical examination and laboratory results Boys and Girls 9 to 14 Years: -Must not have had coitarche and does not plan on becoming sexually active during the vaccination period Women 16 to 26 Years: * Has never had a Papanicolaou (Pap) test or only had normal Pap test results * A lifetime history of 0 to 4 male and/or female sexual partners

Exclusion criteria

All Participants: * Known allergy to any vaccine component * History of severe allergic reaction that required medical intervention * Thrombocytopenia or any coagulation disorder * Females only: participant is pregnant or expecting to donate eggs during day 1 through month 7 * Currently immunocompromised, or been diagnosed with immunodeficiency * Had a splenectomy * Receiving or has received immunosuppressive therapies within the last year * Received any immunoglobulin product or blood-derived product within 3 months * Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial

Design outcomes

Primary

MeasureTime frameDescription
Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Secondary

MeasureTime frameDescription
Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 52 was defined as a titer \>=8 mMU/mL.
Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 6 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 6 was defined as a titer \>=30 mMU/mL.
Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 11 was defined as a titer \>=16 mMU/mL.
Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 16 was defined as a titer \>=20 mMU/mL.
Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 18 was defined as a titer \>=24 mMU/mL.
Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 31 was defined as a titer \>=10 mMU/mL.
Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 33 was defined as a titer \>=8 mMU/mL.
Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 45 was defined as a titer \>=8 mMU/mL.
Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 58 was defined as a titer \>=8 mMU/mL.

Other

MeasureTime frameDescription
Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Month 24Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Month 36Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.
Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Month 36Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).
Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Month 24Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.

Participant flow

Pre-assignment details

A total of 1536 participants were screened and 1518 were randomized into the study.

Participants by arm

ArmCount
Girls 9 to 14 Years V503 at Months 0 and 6
Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
301
Boys 9 to 14 Years V503 at Months 0 and 6
Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
301
Girls and Boys 9 to 14 Years V503 at Months 0 and 12
Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
301
Girls 9 to 14 Years V503 at Months 0, 2, and 6
Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
301
Young Women 16 to 26 Years V503 at Months 0, 2, and 6
Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
314
Total1,518

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003FG004
Overall StudyAdverse Event00200
Overall StudyDeath00010
Overall StudyLost to Follow-up14510621
Overall StudyMissed last follow-up visit10000
Overall StudyPhysician Decision30010
Overall StudyPregnancy20101
Overall StudyProtocol Violation85320
Overall StudyWithdrawal by Subject1521131113

Baseline characteristics

CharacteristicGirls 9 to 14 Years V503 at Months 0 and 6Boys 9 to 14 Years V503 at Months 0 and 6Girls and Boys 9 to 14 Years V503 at Months 0 and 12Girls 9 to 14 Years V503 at Months 0, 2, and 6Young Women 16 to 26 Years V503 at Months 0, 2, and 6Total
Age, Continuous11.4 Years
STANDARD_DEVIATION 1.7
11.5 Years
STANDARD_DEVIATION 1.7
11.4 Years
STANDARD_DEVIATION 1.6
11.4 Years
STANDARD_DEVIATION 1.7
21.0 Years
STANDARD_DEVIATION 2.7
13.4 Years
STANDARD_DEVIATION 4.3
Age, Customized
Between 11 and 12 years
102 Participants102 Participants106 Participants100 Participants0 Participants410 Participants
Age, Customized
Between 13 and 14 years
99 Participants101 Participants95 Participants100 Participants0 Participants395 Participants
Age, Customized
Between 16 and 26 years
0 Participants0 Participants0 Participants0 Participants314 Participants314 Participants
Age, Customized
Between 9 and 10 years
100 Participants98 Participants100 Participants101 Participants0 Participants399 Participants
Sex: Female, Male
Female
301 Participants0 Participants151 Participants301 Participants314 Participants1067 Participants
Sex: Female, Male
Male
0 Participants301 Participants150 Participants0 Participants0 Participants451 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
deaths
Total, all-cause mortality
0 / 2940 / 2960 / 2931 / 3000 / 313
other
Total, other adverse events
53 / 29432 / 29646 / 29355 / 30090 / 313
serious
Total, serious adverse events
6 / 2949 / 2966 / 2936 / 30011 / 313

Outcome results

Primary

Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen1388.9 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen1423.9 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen2941.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen1306.3 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen580.5 mMU/mL
p-value: <0.00195% CI: [2.03, 2.82]ANOVA
p-value: <0.00195% CI: [2.09, 2.88]ANOVA
p-value: <0.00195% CI: [4.32, 5.94]ANOVA
Primary

Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen8004.9 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen8474.8 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen14329.3 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen6996.0 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen3154.0 mMU/mL
p-value: <0.00195% CI: [2.14, 3]ANOVA
p-value: <0.00195% CI: [2.29, 3.15]ANOVA
p-value: <0.00195% CI: [3.84, 5.37]ANOVA
Primary

Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen1872.8 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen1860.9 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen2810.4 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen2049.3 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen761.5 mMU/mL
p-value: <0.00195% CI: [2.05, 2.96]ANOVA
p-value: <0.00195% CI: [2.04, 2.92]ANOVA
p-value: <0.00195% CI: [3.06, 4.45]ANOVA
Primary

Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen1436.3 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen1498.2 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen2117.5 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen1748.3 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen572.1 mMU/mL
p-value: <0.00195% CI: [2.1, 3]ANOVA
p-value: <0.00195% CI: [2.2, 3.12]ANOVA
p-value: <0.00195% CI: [3.08, 4.45]ANOVA
Primary

Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen1030.0 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen1040.0 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen2197.5 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen796.4 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen348.1 mMU/mL
p-value: <0.00195% CI: [2.5, 3.5]ANOVA
p-value: <0.00195% CI: [2.55, 3.5]ANOVA
p-value: <0.00195% CI: [5.36, 7.43]ANOVA
Primary

Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen357.6 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen352.3 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen417.7 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen661.7 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen213.6 mMU/mL
p-value: <0.00195% CI: [1.38, 2.03]ANOVA
p-value: <0.00195% CI: [1.37, 1.99]ANOVA
p-value: <0.00195% CI: [1.61, 2.37]ANOVA
Primary

Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen581.1 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen640.4 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen1123.4 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen909.9 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen364.2 mMU/mL
p-value: <0.00195% CI: [1.36, 1.87]ANOVA
p-value: <0.00195% CI: [1.51, 2.05]ANOVA
p-value: <0.00195% CI: [2.64, 3.61]ANOVA
Primary

Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen1251.2 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen1325.7 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen2444.6 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen1229.3 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Geometric Mean Titers to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen491.1 mMU/mL
p-value: <0.00195% CI: [4.23, 5.86]ANOVA
p-value: <0.00195% CI: [2.15, 3.01]ANOVA
p-value: <0.00195% CI: [2.3, 3.16]ANOVA
Primary

Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV virus-like particles (VLP) type 6 were measured using a competitive Luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen1657.9 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen1557.4 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen2678.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen1496.1 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Geometric Mean Titers to Human Papillomavirus (HPV) Type 6 After the Last Dose of V503 in the Planned Regimen770.9 mMU/mL
p-value: <0.00195% CI: [1.83, 2.53]ANOVA
p-value: <0.00195% CI: [1.73, 2.36]ANOVA
p-value: <0.00195% CI: [2.93, 4.11]ANOVA
Secondary

Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 11 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 11 was defined as a titer \>=16 mMU/mL.

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 11 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
p-value: <0.00195% CI: [-1.1, 2.3]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2.3]Miettinen and Nurminen
p-value: <0.00195% CI: [-1.1, 2.3]Miettinen and Nurminen
Secondary

Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 16 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 16 was defined as a titer \>=20 mMU/mL.

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 16 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
p-value: <0.00195% CI: [-1, 2.2]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2.2]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2.2]Miettinen and Nurminen
Secondary

Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 18 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 18 was defined as a titer \>=24 mMU/mL.

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 18 at Four Weeks After the Last Dose of V503 in the Planned Regimen98.5 Percentage of participants
p-value: <0.00195% CI: [0.1, 3.8]Miettinen and Nurminen
p-value: <0.00195% CI: [0.1, 3.8]Miettinen and Nurminen
p-value: <0.00195% CI: [0.1, 3.8]Miettinen and Nurminen
Secondary

Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 31 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 31 was defined as a titer \>=10 mMU/mL.

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 31 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
p-value: <0.00195% CI: [-1.7, 1.8]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2.1]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2.1]Miettinen and Nurminen
Secondary

Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 33 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 33 was defined as a titer \>=8 mMU/mL.

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 33 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
p-value: <0.00195% CI: [-1.7, 1.7]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2]Miettinen and Nurminen
p-value: <0.00195% CI: [-1.1, 2]Miettinen and Nurminen
Secondary

Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 45 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 45 was defined as a titer \>=8 mMU/mL.

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.3 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.3 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.3 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 45 at Four Weeks After the Last Dose of V503 in the Planned Regimen97.9 Percentage of participants
p-value: <0.00195% CI: [-0.7, 4]Miettinen and Nurminen
p-value: <0.00195% CI: [-0.7, 4]Miettinen and Nurminen
p-value: <0.00195% CI: [0.7, 4.6]Miettinen and Nurminen
Secondary

Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 52 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 52 was defined as a titer \>=8 mMU/mL.

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 52 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
p-value: <0.00195% CI: [-1.7, 1.7]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2.1]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2.1]Miettinen and Nurminen
Secondary

Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 58 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 58 was defined as a titer \>=8 mMU/mL.

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 58 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
p-value: <0.00195% CI: [-1, 2.1]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2.1]Miettinen and Nurminen
p-value: <0.00195% CI: [-1.1, 2.1]Miettinen and Nurminen
Secondary

Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen

Antibodies to HPV VLP type 6 were measured using a competitive Luminex immunoassay. Seroconversion to HPV type 6 was defined as a titer \>=30 mMU/mL.

Time frame: 4 weeks after the last dose of V503 in the planned regimen (Month 7 or Month 13)

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV type, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.2 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Percentage of Participants With Seroconversion to HPV Type 6 at Four Weeks After the Last Dose of V503 in the Planned Regimen99.6 Percentage of participants
p-value: <0.00195% CI: [-1.8, 2]Miettinen and Nurminen
p-value: <0.00195% CI: [-1, 2.3]Miettinen and Nurminen
p-value: <0.00195% CI: [-1.1, 2.3]Miettinen and Nurminen
Other Pre-specified

Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24

Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: Month 24

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureGroupValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5285.1 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 58155.4 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 16900.5 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4537.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 18196.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 33131.2 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 31160.6 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 11169.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 6260.7 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 33121.5 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4531.9 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 11150.6 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 6209.1 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 16801.0 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 18169.6 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5280.9 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 31139.1 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 58149.8 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 18380.8 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 11443.7 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 33341.7 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4562.3 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 58380.2 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 6574.0 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 52199.4 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 162316.2 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 31312.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4586.9 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 6300.7 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 11201.9 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 161041.3 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 18255.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 31260.6 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 33120.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 52150.4 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 58183.7 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3189.6 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 18122.2 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 16461.6 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5876.8 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5273.7 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1198.3 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 6153.2 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3361.3 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4530.7 mMU/mL
Other Pre-specified

Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36

Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Antibody titers were expressed as milli Merck units/mL (mMU/mL).

Time frame: Month 36

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureGroupValue (GEOMETRIC_MEAN)
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 11133.7 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 16673.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 58125.8 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5266.2 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 6209.6 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 18158.9 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4530.6 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 33106.0 mMU/mL
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 31127.8 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 11115.2 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 6160.1 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 16592.6 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 18141.7 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 31106.9 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3395.7 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4526.8 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5263.4 mMU/mL
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 58119.2 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4543.6 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 33240.4 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 52143.2 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 58265.3 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 6401.2 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 11308.2 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 31218.0 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 18276.4 mMU/mL
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 161534.3 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 16792.4 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 18206.5 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 31205.9 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 6232.2 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3395.5 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4566.1 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 58143.0 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 11159.1 mMU/mL
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 52115.9 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5261.5 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 6133.8 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3174.6 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 18104.1 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1182.9 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3352.2 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5864.7 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 16368.9 mMU/mL
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4527.3 mMU/mL
Other Pre-specified

Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24

Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.

Time frame: Month 24

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureGroupValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 698.4 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3197.0 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5898.9 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1698.9 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3397.8 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1898.5 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5296.6 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1198.0 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4588.4 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1699.6 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3396.6 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4585.9 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5899.6 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1195.8 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 696.9 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5295.2 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1895.9 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3194.8 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 699.2 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1898.9 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1199.6 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 58100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3399.2 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4593.9 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5299.2 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3198.5 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 16100 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1198.8 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 699.6 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1699.6 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1899.2 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3197.7 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3398.9 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4596.7 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5299.3 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 58100 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1895.0 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1699.6 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5896.0 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 5297.3 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 1194.8 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 694.0 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3191.5 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 3394.8 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 24Anti-HPV Type 4582.7 Percentage of participants
Other Pre-specified

Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36

Antibodies to HPV VLP types were measured using a competitive Luminex immunoassay. This outcome measure assessed the long-term persistence of antibody response. Seroconversion to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were defined as a titer \>=41, 24, 34, 39, 24, 18, 12, 16, and 12 mMU/mL, respectively. These cutoffs differ from analyses performed on samples collected up to Month 13; the antibody persistence analysis employed a new version of the assay.

Time frame: Month 36

Population: All participants who 1) received all vaccinations in the planned regimen, 2) had a serum sample collected 4 weeks after the last vaccination in the planned regimen, 3) were seronegative at Day 1 for the relevant HPV types, and 4) had no protocol violations that would interfere with evaluation of the immune response.

ArmMeasureGroupValue (NUMBER)
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1895.6 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 695.3 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5293.5 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1697.2 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3394.0 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5898.0 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3194.0 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1194.1 Percentage of participants
Girls 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4583.6 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3396.9 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3191.2 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4581.4 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1192.9 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5899.2 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1698.5 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1894.3 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 691.3 Percentage of participants
Boys 9 to 14 Years V503 at Months 0 and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5293.9 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1897.6 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4587.9 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5298.8 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 58100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3196.5 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 699.2 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 16100 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1199.2 Percentage of participants
Girls and Boys 9 to 14 Years V503 at Months 0 and 12Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3399.2 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1198.8 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 697.9 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1699.2 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1897.3 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3197.7 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3398.1 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4591.2 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5297.7 Percentage of participants
Girls 9 to 14 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5898.8 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3186.0 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1890.8 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5894.8 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 5295.0 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1698.2 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 1192.1 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 692.1 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 4577.8 Percentage of participants
Young Women 16 to 26 Years V503 at Months 0, 2, and 6Antibody Persistence: Percentage of Participants With Seroconversion to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 36Anti-HPV Type 3391.9 Percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026